홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.0
  1. 홈
  2. /화합물

오클라시티닙말레에이트(PF-03394197)

Oclacitinib Maleate

HCID 44631937
새 노트새 반응견적 요청하기
인쇄 미리보기
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
1208319-27-0
표준 SMILES
CNS(=O)(=O)CC1CCC(N(C)c2ncnc3[nH]ccc23)CC1.O=C(O)/C=C\C(=O)O
InChIKey
VQIGDTLRBSNOBV-VQIYXBGXNA-N
분자식
C19H27N5O6S
평균 분자량
453.5 g/mol
단동위원소 질량
453.16820477

개요

See also: Oclacitinib (has active moiety).

이름 및 식별자

우선 이름
Oclacitinib Maleate
IUPAC
(Z)-but-2-enedioic acid;N-methyl-1-[4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl]methanesulfonamide
현지명
오클라시티닙말레에이트(PF-03394197)
영어명
Oclacitinib Maleate(PF-03394197)
분자식
C19H27N5O6S
분자량
453.51

이름 및 동의어

OCLACITINIB MALEATEUNII-VON733L42AVON733L42APF-03394197-11PF 03394197-11OCLACITINIB MALEATE (EMA EPAR: VETERINARY)N-Methyl(trans-4-(methyl-7H-pyrrolo(2,3-d)pyrimidin-4-ylamino)cyclohexyl) methanesulfonamide (2Z)-2-butenedioateN-Methyl[trans-4-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)cyclohexyl] methanesulfonamide (2Z)-2-butenedioateRefChem:580731208319-27-01640292-55-2Oclacitinib (maleate)
이름 더 보기
오클라시티닙말레에이트(PF-03394197)N-methyl-1-((1r,4r)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide MaleateOclacitinib Meleateolatinib maleateOclacitinib Maleate (1:n)Oclacitinib Maleate [VET]Oclacitinib maleate (PF-03394197 maleate)Oclacitinib maleate Good Supplier In China
Oclacitinib maleate [USAN]Apoquel(Z)-but-2-enedioic acid;N-methyl-1-[4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl]methanesulfonamideN-methyl-1-(trans-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide maleate(1:x)MFCD30533388Cis-Oclacitinib MaleateOclacitinib?maleateOclacitinib Maleate(PF-03394197)

물성

구조 계산 물성

극성 표면적
174 Ų
수소 결합 공여자 수
4
수소 결합 수용자 수
10
회전 가능 결합 수
7
무거운 원자 수
31
형식 전하
0
복잡도
606

실험 및 물리화학적 성질

Animal Drugs · 2건

EMA approved medicines: Veterinary medicine

EMA approved medicines: Veterinary medicine

물리화학적 성질

녹는점
135 · 135 - 137°C
저장 조건
-20 °C, · -20°C, Inert atmosphere
용해도
DMSO(약간 용해됨), 메탄올(약간 용해됨, 초음파처리)
물리적 상태
고체
색상
흰색에서 황백색까지
InChIKey
VQIGDTLRBSNOBV-VQIYXBGXNA-N
SMILES
C(/C(=O)O)=C/C(=O)O.N([C@@H]1CC[C@@H](CS(=O)(=O)NC)CC1)(C1N=CN=C2NC=CC=12)C |&1:9,12,r|

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 6건

Danger

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P260, P264, P264+P265, P270, P273, P280, P301+P317, P305+P354+P338, P317, P319, P330, P391, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

유해성 정보

Regulatory InformationOclacitinib maleate: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Hazard Classes and Categories · 2건

Acute Tox. 4 (100%)

Acute Tox. 4 (100%)

안전 데이터

신호 어
Warning
유해·위험 문구
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드 H302

화학 및 산업

응용 분야 · 2건

개요APOQUEL (oclacitinib maleate) was the first selective Janus kinase (JAK) inhibitor to be developed for dogs. It was recently approved for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. In recent years, there has been a significant evolution in understanding regarding the pathophysiology of allergic and atopic diseases. The molecular mechanisms involved in stimulating the itch response have been elaborated (Marsella et al., 2012), and it is now understood that cytokines play a key role in initiating the neuronal itch stimulation which triggers pruritic behavior (scratching, rubbing, chewing, etc.) in dogs. This leads to the establishment of a vicious cycle of itch that exacerbates skin lesions and amplifies defects in the skin barrier function in clinically affected dogs. This progress provided the opportunity to develop new treatments (Marsella et al., 2012). Specifically, Janus kinases play a central role in cytokine signaling and are involved in signal transduction of many pro-inflammatory, pro-allergic, and pruritogenic cytokines including IL-2, IL-4, IL-6, IL-13, and IL-31 that are implicated in allergic conditions (Ong & Leung, 2006; Carmi-Levy et al., 2011).

용도Oclacitinib is labeled to treat atopic dermatitis and itchiness (pruritus) caused by allergies in dogs, though it has also been used to reduce the itchiness and dermatitis caused by flea infestations. It is considered to be highly effective in dogs, and has been established as safe for at least short-term use. Its efficacy equals that of prednisolone at first, though oclacitinib has been found to be more effective in the short term in terms of itchiness and dermatitis, long term safety is unknown. It has been found to have a faster onset and cause less gastrointestinal issues than cyclosporine. While safe in the short term, oclacitinib's long-term safety is unknown. While some say it is best only for acute flares of itchiness, others claim that it is also useful in chronic atopic dermatitis.

관련 반응

0건
반응 기록 만들기

현재 필터 조건에 해당하는 반응 기록이 없습니다.

화합물 노트

불러오는 중…

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
더보기
새 노트새 반응견적 요청하기

데이터베이스 식별자

CAS
1208319-27-0、1640292-55-2
PubChem CID
44631937
ChEMBL
CHEMBL2105739
UNII
VON733L42A
EC Number
962-495-8、968-552-3